Robert Perry, MD
Internal Medicine · Pembroke Pines, FLNPI 1831245554
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 432 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,872 and has fallen 64.5% since, to $664 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 432 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Boehringer Ingelheim$849
- AbbVie$847
- Lilly USA, LLC$556
- Pfizer$518
- Novartis$488
- plus $4K from 33 others
Across 486 payments — averaging $18,870 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.4M
- Amgen$987K
- Astrazeneca UK Limited$902K
- Novartis$817K
- Eli Lilly$709K
- H. Lundbeck A S$679K
- plus $3.7M from 21 others
What the payments were for
- Travel & lodging$2453%
- Food & beverage$8,38897%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 96 | $1,679 |
| Boehringer Ingelheim | 43 | $849 |
| AbbVie(2 entities) | 50 | $847 |
| Lilly USA, LLC | 34 | $556 |
| Pfizer | 28 | $518 |
| Novartis | 3 | $488 |
| Kowa Pharmaceuticals America, Inc. | 18 | $411 |
| Amarin Pharma, Inc. | 19 | $403 |
| AstraZeneca | 15 | $296 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $262 |
| Radius Health, Inc. | 13 | $257 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $247 |
| Sanofi-aventis U.S. LLC | 13 | $245 |
| Merck | 13 | $234 |
| Biohaven Pharmaceuticals, Inc. | 5 | $135 |
| Amgen | 8 | $123 |
| Bayer | 5 | $110 |
| Cook Medical LLC | 1 | $108 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $99 |
| Abbott | 5 | $98 |
| Verity Pharmaceuticals Inc. | 4 | $94 |
| Idorsia Pharmaceuticals US Inc | 3 | $72 |
| Regeneron Healthcare Solutions, Inc. | 2 | $69 |
| Almatica Pharma LLC | 3 | $60 |
| Gilead | 2 | $53 |
| Dexcom, Inc. | 2 | $47 |
| Viiv Healthcare Company | 2 | $46 |
| GSK | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Vivus LLC | 2 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Exeltis, USA Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$125
- NURTEC ODT$109
- Zilver PTX$108
How this compares
$8,649 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $66,022 |
| JardianceEmpagliflozin | 21 | $30,175 |
| MounjaroTirzepatide | 20 | $27,588 |
| EliquisApixaban | 28 | $27,588 |
| JanuviaSitagliptin Phosphate | 23 | $22,110 |
| ProliaDenosumab | 11 | $19,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $12,612 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $9,382 |
| VascepaIcosapent Ethyl | 14 | $9,253 |
| LinzessLinaclotide | 11 | $6,339 |
| Omega-3 Acid Ethyl Esters | 17 | $2,449 |
| Atorvastatin Calcium | 272 | $2,363 |
| Lactulose | 19 | $1,691 |
| Ondansetron OdtOndansetron | 43 | $1,594 |
| Rosuvastatin Calcium | 118 | $1,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,679 | $66,02258 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $849 | $39,55735 claims |
| Lilly USA, LLCMounjaro | $556 | $27,58820 claims |
| PfizerEliquis | $518 | $27,58828 claims |
| MerckJanuvia | $234 | $22,11023 claims |
| AmgenProlia | $123 | $19,24211 claims |
| GSKTrelegy Ellipta | $34 | $12,61214 claims |
| AbbVieLinzess | $847 | $6,33911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Pembroke Pines
- Manuel GonzalezPembroke Pines$37K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.